SCHEMBL11945027

SCHEMBL11945027

CCC1CCC(Oc2c(N3CCN(S(=O)(=O)Cc4ccccc4)CC3)cnn(-c3ccc(F)cc3)c2=O)CC1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.49
▸ ALDH1A1 P00352 5/20 0.41
▸ DCTPP1 Q9H773 1/20 0.41
▸ NPSR1 Q6W5P4 3/20 0.38
▸ PKM P14618 1/20 0.38
▸ CYP2C19 P33261 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ PPARG P37231 1/20 0.38
▸ NCOA2 Q15596 1/20 0.38
▸ NCOA1 Q15788 1/20 0.38
▸ NCOA3 Q9Y6Q9 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11945045 0.92 MAPT (0.48) MAPTALDH1A1DCTPP1NPSR1CYP2C19
SCHEMBL11945036 0.90 MAPT (0.49) MAPTALDH1A1DCTPP1NPSR1CYP2C19
SCHEMBL11945012 0.90 MAPT (0.48) MAPTALDH1A1DCTPP1NPSR1PKM
SCHEMBL11945063 0.89 HSD17B10 (0.44) MAPTALDH1A1NPSR1PKMCYP2C19
SCHEMBL11945031 0.89 MAPT (0.46) MAPTALDH1A1DCTPP1NPSR1CYP2C19
SCHEMBL11943899 0.89 MAPT (0.46) MAPTALDH1A1DCTPP1NPSR1CYP2C19
SCHEMBL11943893 0.88 MAPT (0.47) MAPTALDH1A1DCTPP1NPSR1PKM
SCHEMBL11945037 0.88 MAPT (0.47) MAPTALDH1A1DCTPP1NPSR1CYP2C19
SCHEMBL11943908 0.88 MAPT (0.46) MAPTALDH1A1DCTPP1NPSR1CYP2C19
SCHEMBL11945011 0.88 MAPT (0.48) MAPTALDH1A1DCTPP1NPSR1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPT 2295/4885ALDH1A1 2437/4885DCTPP1 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback